BridgeMD
New treatment option for Diffuse Intrinsic Pontine Gliomas (DIPG)
Official title ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
ClinicalTrials.gov ID: NCT06838676
What this study is testing
What is ACT001?
ACT001 is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for diffuse intrinsic pontine gliomas (dipg).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 to 39
You may be able to join if
- Patients must be ≥ 12 months and ≤ 39 years of age at the time of study enrollment.
- Diagnosis:
- Cohort A: Newly Diagnosed DIPG
- Patients with newly-diagnosed DIPG with typical MRI findings (tumors with a pontine epicenter and diffuse involvement of at least 2/3 of the pons)...
- Patients must have started RT \<42 calendar days from radiographic diagnosis (for non-biopsied DIPG patients only) or definitive surgery, whichever...
You likely can't join if
- AND there is agreement to allow by both the Investigator and Sponsor.) The wash out period between the prior anti-cancer chemotherapy, and enrollment...
- Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea).
- Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth...
- Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent. For agents that have known adverse events occurring beyond...
- Immunotherapy: At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines.
- Monoclonal antibodies: \> 21 days must have elapsed from the infusion of last dose of antibody
See the full eligibility criteria
Who can join
- Patients must be ≥ 12 months and ≤ 39 years of age at the time of study enrollment.
- Diagnosis:
- Cohort A: Newly Diagnosed DIPG
- Patients with newly-diagnosed DIPG with typical MRI findings (tumors with a pontine epicenter and diffuse involvement of at least 2/3 of the pons) with or without biopsy and have completed radiation therapy (RT) within...
- Patients must have started RT \<42 calendar days from radiographic diagnosis (for non-biopsied DIPG patients only) or definitive surgery, whichever is later.
- If a biopsy was performed, the date of surgical biopsy will be considered the date of definitive diagnostic surgery; if a patient underwent two upfront surgeries [e.g., biopsy then debulking], this is the date of the...
- Cohort B: progressive/recurrent DIPG or H3K27-altered HGG OR refractory disease
- Patients with DIPG (no biopsy required), pathologically-confirmed (at diagnosis or recurrence) H3K27-altered DIPG, or extra-pontine H3K27-alteredHGG who have progressive/recurrent or refractory disease
- Progressive/recurrent: patients who have progressive or recurrent disease following frontline treatment must have included at least focal RT. New lesions since completion of frontline RT qualify as progressive disease.
- Refractory disease is defined as: Presence of persistent, measurable, abnormality on conventional MRI that is further distinguished by histology or advanced imaging, OR as determined by the treating physician and...
- Patients with H3K27-altered spinal HGG are eligible.
- Patients with metastatic disease are eligible.
- Disease Status
- Cohort A: patients may have any disease status but must have completed initial radiation therapy (RT) before enrollment.
- Cohort B: Patients must have measurable disease assessable by MRI. Patients may have extra neuronal disease.
- Performance Level: Karnofsky Performance Scale score ≥ 50% for patients \> 16 years of age and Lansky Performance Scale score \> 50% for patients ≤ 16 years of age (applies to all patients) Note: Patients who are unable...
- Prior anti-cancer therapy:
- For Cohort A ONLY:
- Surgery, radiation (focal to disease) and/or steroids (dexamethasone with goal to wean dexamethasone throughout protocol therapy) are permissible. Temozolomide administered concurrently with RT is permissible...
- Patients must enroll and start treatment on study between 28 and 35 calendar days post-completion of RT.
- Patients must have started RT \<42 calendar days of initial diagnosis (defined as the date of diagnostic biopsy or resection; if a patient underwent two upfront surgeries [e.g., biopsy then resection or debulking], this...
- Radiotherapy must have been administered at standard dose of 54 Gy for DIPG patients. Any variances in the radiotherapy dose within 10% of the standard doses outlined above will be discussed with the Study Chair to...
- For Cohort B ONLY: Patients must have fully recovered from the acute treatment related toxicities (defined as \ 6 months (such as ifosfamide-related proteinuria) may be allowed if they are not otherwise described in the
What rules you out
- AND there is agreement to allow by both the Investigator and Sponsor.) The wash out period between the prior anti-cancer chemotherapy, and enrollment must be:
- Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea).
- Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor.
- Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the...
- Immunotherapy: At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines.
- Monoclonal antibodies: \> 21 days must have elapsed from the infusion of last dose of antibody
- Radiation therapy:
- All Cohort B patients: Patients must have received their last fraction of focal irradiation to new sites of progressive disease \> 14 days prior to enrollment.
- Patients who received CSI must have received their last fraction \> 3 months prior to enrollment.
- Progressive/recurrent disease: Patients who received re-irradiation to primary disease must have received their last fraction \> 3 months prior to study enrollment.
- Refractory Disease:
- Patients must have completed frontline RT \> 6 months prior to enrollment.
- Patients who received re-irradiation to primary disease must have received their last fraction \> 3 months prior to study enrollment.
- Stem Cell Transplant: Patients must be ≥ 3 months since autologous stem cell transplant. Patients who received allogenic stem cell transplant or solid organ transplant are not eligible for study
- Organ Function Requirements (applies to all patients)
- Adequate bone marrow function defined as:
- Peripheral absolute neutrophil count (ANC) \> 1000/mm³
- Platelet count \> 100,000/mm³ (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
- Adequate renal function defined as:
- Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m² or
- A serum creatinine based on age/gender as follows (Schwartz et al. J. Peds, 106:522, 1985): Age Maximum Serum Creatinine (mg/dL) Male Female 1 to \< 2 years 0.6 0.6 2 to \< 6 years 0.8 0.8 6 to \< 10 years 1.0 1.0 10 to...
- Adequate liver function defined as:
- total bilirubin must be \</=1.5X institutional ULN for age
- AST (serum glutamic-oxaloacetic transaminase [SGOT]) / ALT (serum glutamic-oxaloacetic transaminase [SGPT]) ≤ 2.5 × institutional upper limit of normal
- Serum albumin ≥ 2 g/dL
- Adequate cardiac function defined as:
- Ejection fraction of ≥ 50% by echocardiogram
- QTc ≤ 450 msec (by Bazett formula)
- For Cohort B: Adequate neurologic function defined as:
- Patients with seizure disorders may be enrolled if seizures are well- controlled. Well controlled is defined by no increase in seizure frequency in the 7 days prior to enrollment.
- Patients with neurological deficits should have deficits that are stable for at least the 7 days prior to enrollment.
- Informed Consent: All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.
- Absence of other clinically significant concomitant active medical disorder, based on the investigator's judgement. Exclusion Criteria: A patient who meets any of the following exclusion criteria will not be eligible in...
- Cohort A only: Patients with metastatic disease.
- Concomitant medications:
- Corticosteroids:
- Cohort A - Patients receiving corticosteroids are eligible regardless of dosing
- Cohort B - Patients receiving corticosteroids who have been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are eligible
- Anti-cancer Agents: Patients who are currently receiving other anti-cancer agents are not eligible (Refer study inclusion criteria relating to anti-cancer therapies)
- Cohort A - Patients that have received any anti-cancer treatment other than surgery, RT, temozolomide concurrent with RT, and/or previous bevacizumab with appropriate washout period are not eligible.
- Investigational Drugs: Patients who are currently receiving another investigational drug are not eligible.
- Anticonvulsants should be used as clinically indicated. The use of enzyme inducing anticonvulsants is not permitted
- LHRH agonist / antagonists are not permitted
- High Dose Biotin (B7) supplements are not permitted
- Concomitant medications used with caution: selective serotonin reuptake inhibitor (SSRI) such as Lexapro, Fluoxetine (Prozac), fluvoxamine (Luvox), paroxetine (Paxil), sertraline (Zoloft), citalopram (Celexa), and...
- Infection: Patients who currently have an uncontrolled infection (in the opinion of the PI) are not eligible.
- Patients who have received a prior solid organ transplantation are not eligible.
- Pregnant or breast-feeding women will not be entered on this study due to unknown risks of fetal and teratogenic adverse events as seen in animal/human studies. Pregnancy tests must be obtained in girls who are...
- Patients of childbearing or child fathering potential must agree to use adequate contraceptive methods (hormonal or barrier method of birth control; abstinence) while being treated on this study and for 3 months after...
- Patients who are in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.
- Patients who have previously received either ACT001 or parthenolide are not eligible.
The study team makes the final eligibility decision.
Where it's taking place
- Aurora, Colorado, United States
- Washington D.C., District of Columbia, United States
- Miami, Florida, United States
- Atlanta, Georgia, United States
- Ann Arbor, Michigan, United States
- St Louis, Missouri, United States
- Durham, North Carolina, United States
- Cincinnati, Ohio, United States
- Columbus, Ohio, United States
- Philidelphia, Pennsylvania, United States
- Houston, Texas, United States
- Seattle, Washington, United States
- Randwick, New South Wales, Australia
- South Brisbane, Queensland, Australia
- Melbourne, Victoria, Australia
- Perth, Western Australia, Australia
- Toronto, Ontario, Canada
- Montreal, Quebec, Canada
- Heidelberg, Baden-Wurttemberg, Germany
- Auckland, Grafton, New Zealand
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 12 months to 39 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Aurora, Colorado, United States; Washington D.C., District of Columbia, United States; Miami, Florida, United States; Atlanta, Georgia, United States; Ann Arbor, Michigan, United States; St Louis, Missouri, United States and 14 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.